<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03524638</url>
  </required_header>
  <id_info>
    <org_study_id>18-0282</org_study_id>
    <nct_id>NCT03524638</nct_id>
  </id_info>
  <brief_title>VSL3's Effect on Colorectal Anastomosis and Local Recurrence</brief_title>
  <official_title>VSL3's Effect on Colorectal Anastomosis and Local Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine whether the administration of VSL3 after colorectal surgery has any effect on
      anastomotic leak and local recurrence
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized study of VSL3 after colorectal surgery. Subjects will be randomized 1:1 to either
      VSL3 or no VSL3.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of Anastomotic Leak</measure>
    <time_frame>Hospital discharge, 2 and 4 weeks post-treatment. Then every 3 months for 1 year.</time_frame>
    <description>Development of anastomotic leak will be evaluated by sigmoidoscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local Recurrence</measure>
    <time_frame>Every three months for 1 year post hospital discharge.</time_frame>
    <description>CT scans will be performed every 3 months after hospital discharge to check disease status</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colorectal surgery with administration of VSL3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colorectal Surgery alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VSL3</intervention_name>
    <description>Colorectal surgery plus administration of VSL3 on post-operative day 2.</description>
    <arm_group_label>ARM A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Colorectal Surgery</intervention_name>
    <description>Colorectal surgery alone</description>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_label>ARM B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Diagnosis of biopsy proven rectal cancer (CT/MRI)

          -  Willing and able to comply with protocol requirements

          -  Able to tolerate surgery

          -  Able to comprehend and have signed the Informed Consent

          -  Absence of metastatic disease

          -  Clinical performance status of ECOG 0 or 1

          -  Life expectancy of greater than 3 months

          -  Planned ileostomy as part of their routine care

        Exclusion Criteria:

          -  Severe or refractory ulcerative colitis defined as Mayo Score of greater than or equal
             to 10, endoscopic disease activity score 3

          -  Untreated enteric infection (positive stool test for any of the following: clostridium
             difficile, salmonella, shigella, yersinia, campylobacter, enteropathogenic E. coli or
             other enteric infection at the discretion of the Investigator

          -  Severe immunodeficiency, inherited or required (e.g. HIV, chemotherapy or radiation
             therapy)

          -  Patients with the following laboratory abnormalities: absolute neutrophil count
             &lt;1000/ul, platelets &lt;50 x 10^9/L, hemoglobin &lt;6.5g/dL

          -  History of anaphylaxis (severe allergic reaction) to food allergens (e.g. tree nuts,
             shellfish)

          -  Active intestinal obstruction

          -  Non-steroidal anti inflammatory medications (NSAIDs) as long-term treatment, defined
             as for at least 4 days per week each month

          -  Cholestyramine use

          -  Any condition in which the Investigator thinks VSL3 administration may pose a health
             risk (e.g. severely immunocompromised)

          -  Simultaneous participation in another interventional clinical trial

          -  Patients who are pregnant, breast feeding or planning pregnancy during study trial
             period

          -  Patients with any other signification medical condition that could confound or
             interfere with evaluation of safety, tolerability or prevention compliance with the
             study protocol at the discretion of the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Russell Farmer, MD</last_name>
    <phone>502-852-1727</phone>
    <email>russell.farmer@louisville.edu</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Russell Farmer</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

